Prevalence of Metabolic Syndrome among Patients with Major Depressive Disorder – Differences Between Newly Diagnosed First Episode and Recurrent Disease by Rudolf Ljubičić et al.
Coll. Antropol. 37 (2013) 4: 1065–1069
Original scientific paper
Prevalence of Metabolic Syndrome among
Patients with Major Depressive Disorder –
Differences Between Newly Diagnosed First
Episode and Recurrent Disease
Rudolf Ljubi~i}1, Hrvoje Jakovac2, Ivana Ljubi~i} Bistrovi}3, Tanja Fran~eski1,
Ana Kovak Mufi}1 and Dalibor Karlovi}1
1 University of Zagreb, University Hospital Center »Sestre milosrdnice«, Department of Psychiatry, Zagreb, Croatia
2 University of Rijeka, School of Medicine, Department of Physiology and Immunology, Rijeka, Croatia
3 University of Rijeka, University Hospital Centre Rijeka, Department of Psychiatry, Rijeka, Croatia
A B S T R A C T
The objective of the present study was to assess differences in prevalence of the metabolic syndrome among depressed
patients in regard to the duration of the illness (first episode versus recurrent episodes). A total of 190 patients suffering
from major depressive disorder were included in the study, diagnosed according to International classification of disor-
ders, 10th revision1. The same criteria were used to divide participants into two groups: first episode major depressive
disorder and major depressive disorder with recurrent episodes. The metabolic syndrome was defined according to the
criteria of the American National Cholesterol Education Program-Treatment Panel III2. Results showed that metabolic
syndrome is significantly more prevalent in patients with recurrent major depressive disorder (45.2%) compared to pa-
tients with first episode of major depressive disorder (27.3%), mainly due to differences in plasma glucose, triglycerides
and HDL-cholesterol levels. These findings indicate the importance of the duration of depression and the number of re-
curring episodes as factors involved in etiopathogenesis of the associated metabolic syndrome.
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Introduction
Metabolic syndrome is a clinical phenomenon that in-
cludes increased abdominal fat, increased fasting glucose
levels with the development of insulin resistance, in-
creased blood pressure and serum lipid disorders3. Pa-
tients with metabolic syndrome have an increased risk
for the development of type II diabetes and cardiovascu-
lar disease4. Epidemiological data revealed a high inci-
dence of metabolic syndrome among the psychiatric po-
pulation5,6. The prevalence of metabolic syndrome in
patients with major depressive disorder (MDD) ranges
from 25 to more than 50%, depending on the study, popu-
lation and criteria of diagnosing metabolic syndrome6–13.
Several prospective cohort studies have clearly pointed
to the depressive disorder as a predictor of metabolic syn-
drome development14–16. Moreover, prospective study
that lasted for 15 years and included 4256 participants,
as a part of Vietnam Experience Study, established that
major depressive disorder predicts cardiovascular mor-
tality after adjusting for a range of covariates15.
Common development of the metabolic syndrome fol-
lowing depression is often attributed to the »unhealthy«
lifestyle as part of depressive disorder5,6. Namely, low-
ered mood with an accompanying loss of libido and
hypobulia usually influences patient habits, which then
leads to a disbalance of bodily homeostasis and develop-
ment of metabolic syndrome. Birth cohort study con-
ducted by Gaysina and colleagues14 found that early on-
set of depressive symptomatology (adolescence) is a
strong predictor of obesity later in life, in comparison to
the late onset of depression (adult age). However, so far it
is not known whether there is any correlation between
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metabolic syndrome development and duration or sever-
ity of depression.
Considering these insights, the objective of present
study was to assess differences in prevalence of the meta-
bolic syndrome among depressed patients regarding the
duration of the illness (first episode versus recurrent epi-
sodes).
Subjects and Methods
Subjects and diagnostic criteria
The MDD study group consisted of 190 patients, 44
with first episode MDD (F-MDD) and 146 with recurrent
MDD (R-MDD). The F-MDD group included 28 males
and 16 females. The R-MDD group included 87 males
and 59 females. Sociodemographic and clinical parame-
ters of all included subjects are presented in Table 1. All
subjects with MDD were inpatients. The inclusion crite-
ria for this study were the diagnosis of MDD, using the
International classification of disorders, 10th revision
(ICD-10)1. and the absence of any other psychiatric disor-
der (including anxious and somatization disorders and
chronic fatigue syndrome). Patients with any use of psy-
choactive compounds including alcohol in their medical
history were excluded from the study. Furthermore, pa-
tients that had taken any anti-inflammatory or anti-ag-
gregation medicines, as well as statins, were also ex-
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TABLE 1
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df = 2, p = 0.171
Age in years
(mean±SD)
50.1 ± 12.7 52.5 ± 10.7 50.0 ± 10.5
F = 2.553
df = 2, p = 0.079
Systolic blood pressure
(mean±SD)
125.7 ± 14.5 129.6 ± 13.5 127.2 ± 12.5
F = 1.797
df = 2, p = 0.168
Diastolic blood pressure
(mean±SD)
77.1 ± 11.9 80.9 ± 10.7 80.1 ± 7.5
F = 2.305
df = 2, p = 0.102
Waist circumference
(mean±SD)
93.7 ± 14.3 95.0 ± 13.4 94.3 ± 12.2
F = 0.161
df = 2, p = 0.852
BMI
(mean±SD)
26.7 ± 3.9 27.6 ± 4.6 27.7 ± 4.0
F = 0.772
df = 2, p = 0.463
Cholesterol (mmol/L)
(mean±SD)
5.9 ± 1.4 5.9 ± 1.4 5.9 ± 1.0
F = 0.027
df = 2, p = 0.973
Triglycerides (mmol/L)
(mean±SD)
1.8 ± 1.6 2.3 ± 1.4 1.7 ± 1.1
F = 5.050
df = 2, p < 0.01
HDL-cholesterol (mmol/L)
(mean±SD)
1.2 ± 0.3 1.4 ± 0.4 1.4 ± 0.3
F = 9.213
df = 2, < 0.01
LDL-cholesterol (mmol/L)
(mean±SD)
3.7 ± 1.2 3.7 ± 1.1 3.7 ± 0.9
F = 0.024
df = 2, = 0.976
Glucose (mmol/L)
(mean±SD)
4.8 ± 1.0 5.8 ± 1.9 5.4 ± 1.4
F = 6.804
df = 2, < 0.01
cluded. Exclusion criteria also included disorders that
could be associated with MDD, such as neurological dis-
eases, untreated hypothyroidism or poorly controlled di-
abetes mellitus, and immunological and autoimmune
diseases. All investigated patients were screened for acu-
te infection by body temperature measurement, erythro-
cyte sedimentation rate and leukocyte count17. All pa-
tients having increased body temperature over 36.7 °C,
or a leukocyte count greater than 9×109/L, or an erythro-
cyte sedimentation rate greater than 10 mm/h were ex-
cluded from the study. None of the patients included in
this study had taken any psychotropic medication for 30
or more days prior to the study. The control group con-
sisted of 242 healthy subjects (153 males and 89 females),
mostly hospital workers, medical students and voluntary
blood donors, without any psychiatric or somatic disor-
ders, alcohol or other drugs abuse, which was examined
by self-report. Informed consent was obtained from all
included subjects after a complete and extensive descrip-
tion of the study profile. The study was approved by Eth-
ics Committee of the University Hospital Center.
The study included all patients that had been admit-
ted for inpatient treatment with the diagnosis of MDD in
the period from January 2010 to May 2012. All MDD pa-
tients presenting the above described exclusion criteria
were excluded from the study. Upon meeting the inclu-
sion criteria according to the described criteria for first
and recurrent MDD based on ICD 10 criteria, patients
were divided into the first episode MDD group and recur-
rent episode MDD group.
Variables of disease features (number of episodes, du-
ration of MDD in years) were obtained from the struc-
tured clinical interview based on the Mini International
Neuropsychiatric Interview (MINI)18 and were perfor-
med by a trained psychiatrist. Body mass index (BMI)
was calculated using the accepted formula (BMI=weight
in kilograms/height in square meters). The diagnosis of
metabolic syndrome was verified according to the criteria
of the American National Cholesterol Education Pro-
gram (NCEP) Treatment Panel III (ATP III)1,4. The
NCEP ATP III defines metabolic syndrome as the pres-
ence of three or more of the following criteria: waist cir-
cumference >102 cm in men, >88 cm in women; hyper-
triglyceridemia <1.7 mmol/L; HDL-cholesterol >1.03
mmol/L in men, >1.29 mmol/L in women; blood pressure
<130/85 mm Hg; and fasting glucose <5.6 mmol/L.
Biochemical measurements
Blood samples were taken from patients for the analy-
sis of metabolic parameters. Blood samples were taken
from the cubital vein in two vacuumed eprouvettes in the
morning, after 12 h of fasting and after a 30 minute
pause: one eprouvette without an anticoagulant for the
determination of glucose and lipids.
Triglycerides, glucose and HDL cholesterol were de-
termined with enzyme methods using commercial re-
agents (Olympus Diagnostics, Germany). In our labora-
tory, the value of the inter-assay CV was 4.4% 1.5% for
glucose, 2.4% for triglycerides, and 2.1% for HDL choles-
terol.
Statistical analyses
The normal distribution was assessed for all mea-
sures and for each group using the Kolmogorov-Smirnov
test. Sociodemographic and clinical characteristics of pa-
tients and healthy control subjects were compared in fre-
quencies using the Chi-square test and for continuous
variables using analysis of variance (ANOVA) with Bon-
ferroni post hock test for comparation between groups.
Association of metabolic syndrome components with first
episode or recurrent MDD was tested with logistic re-
gression analysis where dichotomous dependent variable
was first episode MDD and recurrent MDD. Statistical
significance was based upon value of a=0.01.
Statistics was done with SPSS software (SPSS for
Windows 17.0, SPSS, Chicago, IL, USA).
Results
We found that prevalence of completely developed
metabolic syndrome diagnosed according to ATP III cri-
teria among patients with first MDD episode was 27.3%,
whereas in those with recurrent disease prevalence was
45.2%. The analysis showed the existence of statistically
significant differences between patients with first epi-
sode and recurrent MDD regarding plasma triglycerides,
HDL and glucose concentrations (Table 1). The Post
hock Bonferroni test was done to establish the reason of
significant difference and between which groups.
The above mentioned significant difference in triglyc-
erides occurred due to statistically significant differences
in triglycerides’ values in MDD patients with more de-
pressive episodes and the control group (p<0.01). There
is also a statistically significant difference in HDL choles-
terol values between first episode and recurrent MDD (p
<0.01), as well as between first episode MDD and the
control group (p<0.01). Statistically significant differ-
ences were also observed in plasma glucose values be-
tween first episode and recurrent MDD (p<0.01).
The logistic regression was performed in order to ex-
amine the connection of first episode and recurrent MDD
with values of the exact components of the metabolic
syndrome according to ATP III criteria. In the group of
the MDD participants, the model in which one or more
episodes were correlate variable were statistically signifi-
cant (c²=35.612; df=6; p<0.01).
The model completely explains 19.2–28.2% (Cox &
Snell r2=0.192; Negelkerke r2=0.282) and correctly qual-
ifies 79,6 % of the cases (Table 2). HDL cholesterol and
glucose values were significantly associated with recur-
rent MDD.
Discussion
In the present study, which included a total of 190 de-
pressive inpatients, we found that prevalence of meta-
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bolic syndrome in patients with first episode MDD was
27.3%, whereas in patients with recurrent MDD it was
45.2%, independently of age and gender. Results indicate
that long lasting depression and recurrence of depressive
episodes significantly increase the risk of metabolic syn-
drome. Difference in the prevalence of the metabolic syn-
drome was present mainly due to differences in plasma
glucose, triglycerides and HDL-cholesterol levels between
analyzed groups.
According to previous studies, the prevalence of meta-
bolic syndrome among patients with depression varies
from 25 to more than 50%5–13, which corresponds to the
results of present study. The prevalence of metabolic syn-
drome in patients with first episode of MDD matches the
lower limit, while the prevalence among patients with re-
current MDD coincides with the upper limit of a wide
range of prior established prevalence.
To our knowledge, so far only one study took into con-
sideration the duration of depression as a factor influenc-
ing the prevalence of metabolic changes later in life14.
Gaysina and colleagues in a prospective study found that
early onset of depression, in comparison with late onset,
is a strong predictor of later obesity, but not of a com-
pletely developed metabolic syndrome. Moreover, that
study did not take into account the recurring nature of
depressive disorder and the appearance / absence of de-
pressive episodes through the considered period of life.
In our cross-sectional study, we found that completely de-
veloped metabolic syndrome is significantly more preva-
lent in patients with multiple depressive episodes and
overall longer duration of depressive symptomatology.
Taken together, it can be generally concluded that long
lasting depression, compared with newly diagnosed first
depressive episode, is associated with a higher rate of
metabolic syndrome development.
Significantly higher prevalence of the metabolic syn-
drome among patients with recurrent MDD could be at-
tributed to more common occurrence of depression-in-
duced behavioral changes, such as sedentary lifestyle,
overeating and general carelessness, which in turn re-
quire a longer period of time to entirely manifest their
etiopathogenetic effects as completely developed meta-
bolic syndrome5,19.
Similarly, initiated pathophysiological mechanisms
which overlap in both disorders, such as disturbed hypo-
thalamic-pituitary axis activity, hypercytokinemia and
dysregulated serotonergic neurotransmission20–27, in pa-
tients with recurrent MDD »have enough time« to gradu-
ally, through a continuum of metabolic changes, finally
result in a complete metabolic syndrome. Because this
study did not include measurements of biological param-
eters associated with depressive disorder, such as plasma
concentrations of serotonin, cortisol, proinflammatory
cytokines and other inflammatory markers, further in-
vestigations are needed to elucidate which of them are
related with a high prevalence of metabolic syndrome
among depressed patients. Also, further research is nec-
essary to determine whether there is any relation be-
tween the severity of depression and the metabolic syn-
drome occurrence.
Conclusion
This study provides the first evidence of a higher
prevalence of metabolic syndrome among patients with
recurrent MDD compared to patients with first episode
MDD, pointing to the importance of the feature of recur-
rence and duration of depressive symptomatology in the
etiopathogenesis of metabolic syndrome. The results
suggest that metabolic syndrome in depressive patients
could be considered as an extreme of a continuum of met-
abolic disturbances initiated with depression, probability
of which increases with emergence of following depres-
sive episodes. In this regard and in order to promptly ini-
tiate preventive measures for cardiovascular and cere-
brovascular diseases it is very much advisable to multidis-
ciplinary and systematically monitor depressive patients
during their illness. Further studies are needed to eluci-
date if there is any relationship between the severity of
depressive symptoms and prevalence of metabolic syn-
drome, as well as to determine the biological substrates
of the present findings.
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TABLE 2
LOGISTIC REGRESSION FOR THE GROUP OF MDD PATIENTS, WHERE ONE OR RECURRED EPISODES WERE DEPENDENT
VARIABLES, WHILE SYSTOLIC BP, DIASTOLIC BP, WAIST CIRCUMFERENCE, TRIGLYCERIDES, HDL CHOLESTEROL AND GLUCOSE




Wald df p Exp(B)
Systolic blood pressure 0.13 0.023 0.311 1 0.577 1.013
Diastolic blood pressure 0.006 0.027 0.053 1 0.817 1.006
Waist circumference 0.013 0.015 0.681 1 0.409 1.013
Triglycerides (mmol/L) 0.112 0.182 0.375 1 0.540 1.118
HDL -cholesterol (mmol/L) 2.271 0.655 12.023 1 0.001 9.693
Glucose (mmol/L) 0.694 0.257 7.288 1 0.007 2.002
R E F E R E N C E S
1. WORLD HEALTH ORGANIZATION (WHO), International statis-
tical classification of diseases and health related problems (Tenth revi-
sion) (WHO, GENEVA, 2004). — 2. NATIONAL CHOLESTEROL EDU-
CATION PROGRAM (NCEP) EXPERT PANEL ON DETECTION,
EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTE-
ROL IN ADULTS (ADULT TREATMENT PANEL III), Circulation, 106
(25) (2002) 3143. — 3. ECKEL RH, GRUNDY SM, ZIMMET PZ, Lancet,
365(9468) (2005) 1415. DOI: 10.1016/S0140-6736(05)66378-7 — 4.
GRUNDY SM, CLEEMAN JI, DANIELS SR, DONATO KA, ECKEL
RH, FRANKLIN BA, GORDON DJ, KRAUSS RM, SAVAGE PJ, SMITH
SC JR, SPERTUS JA, COSTA F, AMERICAN HEART ASSOCIATION,
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE, Circulation,
112(17) (2005) 2735. DOI: 10.1161/CIRCULATIONAHA.105.169404 —
5. KOZUMPLIK O, UZUN S, Psychiatr Danub, 23(1) (2011), 84. — 6.
HEISKANEN TH, NISKANEN LK, HINTIKKA JJ, KOIVUMAA-HON-
KANEN HT, HONKALAMPI KM, HAATAINEN KM, VIINAMÄKI HT, J
Clin Psychiatry, 67 (2006) 1422. DOI: 10.4088/JCP.v67n0913 — 7. EVER-
SON-ROSE SA, HOUSE JS, MERO RP, Psychosom Med, 66(6) (2004),
823. DOI: 10.1097/01.psy.0000145903.75432.1f — 8. KINDER LS, CAR-
NETHON MR, PALANIAPPAN LP, KING AC, FORTMANN SP, Psycho-
som Med, 66(3) (2004) 316. DOI: 10.1097/01.psy.0000124755.91880.f4 —
9. KOPONEN H, JOKELAINEN J, KEINÄNEN-KIUKAANNIEMI S,
KUMPUSALO E, VANHALA M, J Clin Psychiatry 69(2) (2008) 178. DOI:
10.4088/JCP.v69n0202 — 10. OKAMURA F, TASHIRO A, UTUMI A,
IMAI T, SUCHI T, TAMURA D, SATO Y, SUZUKI S, HONGO M, Metabo-
lism, 49(10) (2000) 1255. DOI: 10.1053/meta.2000.9515 — 11. PULKKI-
-RÅBACK L, ELOVAINIO M, KIVIMÄKI M, MATTSSON N, RAITAKA-
RI OT, PUTTONEN S, MARNIEMI J, VIIKARI JS, KELTIKANGAS-
-JÄRVINEN L, Health Psychol, 28(1) (2009) 108. DOI: 10.1037/a0012646
— 12. RÄIKKÖNEN K, MATTHEWS KA, KULLER LH, Diabetes Care,
30(4) 2007 872. DOI:10.2337/dc06-1857 — 13. RICHTER N, JUCKEL G,
ASSION HJ, Eur Arch Psychiatry Clin Neurosci, 260(1) 2010 41. DOI:
10.1007/s00406-009-0013-5 — 14. GAYSINA D, PIERCE M, RICHARDS
M, HOTOPF M, KUH D, HARDY R, Brain Behav Immun, 25(4) 2011 750.
DOI:10.1016/j.bbi.2011.01.019 — 15. PHILLIPS AC, BATTY GD, GALE
CR, DEARY IJ, OSBORN D, MACINTYRE K, CARROLL D, Psychosom
Med, 71(4) 2009 395. DOI: 10.1097/PSY.0b013e31819e6706 — 16. CAPU-
RON L, SU S, MILLER AH, BREMNER JD, GOLDBERG J, VOGT GJ,
MAISANO C, JONES L, MURRAH NV, VACCARINO V, Biol Psychiatry
64(10) (2008) 896. DOI: 10.1016/j.biopsych.2008.05.019 — 17. THOMAS
SA, Nurs Spectr, 23 (1998) 8. — 18. SHEEHAN DV, LECRUBIER Y,
SHEEHAN KH, AMORIM P, JANAVS J, WEILLER E, HERGUETA T,
BAKER R, DUNBAR GC, J Clin Psychiatry, 59(S20) (1998) 22. — 19.
KASSI E, PERVANIDOU P, KALTSAS G, CHROUSOS G, BMC Med 9
(2011) 48. DOI: 10.1186/1741-7015-9-48 — 20. KARLOVI] D, SERRET-
TI A, VRKI] N, MARTINAC M, MAR^INKO D, Psychiatry Res, 198(1)
(2012) 74. DOI: 10.1016/j.psychres.2011.12.007 — 21. SILI] A, KARLO-
VI] D, SERRETTI A, J Affect Disord, 141(1) (2012) 72. DOI: 10.1016/j.
jad.2012.02.019 — 22. VIDRIH B, KARLOVI] D, PASI] MB, UREMO-
VI] M, MUFI] AK, MATO[I] A, Acta Clin Croat, 51(3) (2012) 403. —
23. CRNKOVI] D, BULJAN D, KARLOVI] D, KRMEK M, Acta Clin
Croat, 51(1) (2012) 25. — 24. O’KEANE V, FRODL T, DINAN TG,
Psychoneuroendocrino, 37(10) (2012) 1589. DOI: 10.1016/j.psyneuen.
2012.03.009 — 25. PALAZIDOU E, Br Med Bull, 101 (2012) 127. DOI:
10.1093/bmb/lds004 — 26. MCNAMARA RK, LOTRICH FE, Expert Rev
Neurother, 12(9) (2012) 1143. DOI: 10.1586/ern.12.98 — 27. BEUMER W,
GIBNEY SM, DREXHAGE RC, PONT-LEZICA L, DOORDUIN J, KLEIN
HC, STEINER J, CONNOR TJ, HARKIN A, VERSNEL MA, DREXHA-
GE HA, J Leukoc Biol, 92(5) (2012) 959. DOI: 10.1189/jlb.0212100.
R. Ljubi~i}
University of Zagreb, University Hospital Center »Sestre milosrdnice«, Department of Psychiatry, Vinogradska cesta 29,
10000 Zagreb, Croatia
e-mail: rudolf.ljubicic@yahoo.com
PREVALENCIJA METABOLI^KOG SINDROMA U DEPRESIVNIH BOLESNIKA
– RAZLIKE IZME\U NOVODIJAGNOSTICIRANE PRVE EPIZODE I POVRATNE BOLESTI
S A @ E T A K
Cilj ovog rada bio je utvrditi postoje li razlike u prevalenciji metaboli~kog sindroma izme|u depresivnih bolesnika s
obzirom na trajanje depresivne simptomatologije (prva epizoda nasuprot povratnom poreme}aju). U studiju je bilo
uklju~eno ukupno 190 bolesnika s velikim depresivnim poreme}ajem dijagnosticiranim prema Me|unarodnoj klasifi-
kaciji bolesti, 10. revidirano izdanje (MKB 10)1. Ispitanici su bili podijeljeni u dvije skupine – skupinu bolesnika u kojih
je dijagnosticirana prva epizoda velikog depresivnog poreme}aja, te u skupinu bolesnika sa potvr|enom dijagnozom
povratnog velikog depresivnog poreme}aja. Metaboli~ki sindrom je dijagnosticiran prema NCEP-ATP III kriterijima2.
Rezultati su pokazali da je metaboli~ki sindrom imao znatno ve}u prevalenciju me|u bolesnicima s povratnim depre-
sivnim poreme}ajem (45,2%) no u bolesnika u kojih je dijagnosticirana prva epizoda povratnog depresivnog poreme}aja
(27,3%). Ove razlike bile su prisutne uglavnom zbog razlika u plazmatskim koncentracijama glukoze, triglicerida i
HDL-kolesterola izme|u ispitivanih skupina bolesnika. Rezultati studije upu}uju na va`nost trajanja depresivne simp-
tomatologije te ponavljanja depresivnih epizoda kao ~imbenika uklju~enih u etiopatogenezu pridru`enog metaboli~kog
sindroma.
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